Novo Nordisk and Eli Lilly have spoken out against the use of their GLP-1 medications for cosmetic weight loss, emphasizing the proper use of their medications.
The stock market plunge in the past few weeks because of soaring inflation and a hawkish central bank has also resulted in a drawdown of investments in the biotech sector.
Baron Funds, an asset management firm, published its “Baron Health Care Fund” first quarter 2022 investor letter – a copy of which can be downloaded here.